Last reviewed · How we verify
Tralokinumab 300 mg, Q2W
At a glance
| Generic name | Tralokinumab 300 mg, Q2W |
|---|---|
| Also known as | CAT-354 |
| Sponsor | MedImmune LLC |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2) (PHASE3)
- Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function (PHASE2)
- A Study to Evaluate the Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma (PHASE3)
- A Safety and Efficacy Study of Tralokinumab in Adults With Asthma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |